Le Lézard
Classified in: Health
Subject: SVY

Global Acromegaly and Gigantism Drugs Market 2018-2022: Growing Popularity of Drugs Over Surgeries & Focus on Long-Acting Novel Formulations


DUBLIN, March 14, 2018 /PRNewswire/ --

The "Global Acromegaly and Gigantism Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global acromegaly and gigantism drugs market to grow at a CAGR of 3.03% during the period 2018-2022.

Global Acromegaly and Gigantism Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is growing popularity of drugs over surgeries. Although pharmacological therapies for acromegaly treatment have been there for more than a decade, the demand from individuals for these non-surgical options is increasing on a regular basis. The prime reason for the shift in choice can be attributed to low success rates of acromegaly surgeries.

For instance, as per the NIH, in a study involving total 62 subjects, 31 subjects were treated by transsphenoidal surgery, and four subjects were cured. Out of these 31 subjects treated with transsphenoidal surgery, post-operative anterior pituitary hormone deficiency was seen in 10 subjects, and diabetes insipidus got developed in one subject.

According to the report, one of the major drivers for this market is Strong pipeline. The presence of a large number of molecules in pipeline represents significant opportunities for market growth. Around 42.86% of the total pipeline molecules for acromegaly and gigantism are in Phase III stage of development and are expected to be launched during the forecast period. Companies are working toward the development of drugs that cater to the unmet medical needs for this condition.

For instance, octreotide capsules by Chiasma and Pasireotide long-acting release (LAR) by Novartis for individuals with acromegaly who are inadequately treated with somatostatin analogs, and combination therapy of lanreotide autogel and pegvisomant by Ipsen are in Phase III stage of development for the treatment of acromegaly.

Further, the report states that one of the major factors hindering the growth of this market is Difficulty in diagnosis. In the last two decades, numerous important advancements took place in the domain such as the emergence of assays with improved sensitivity for IGF-1 and GH, development of automated software for evaluating physical changes associated with the disease, and widespread pituitary examination using magnetic resonance imaging (MRI). Despite all these advancements, acromegaly remains clinically under-diagnosed.

Key vendors

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

PART 05: MARKET LANDSCAPE

PART 06: MARKET SIZING

PART 07: FIVE FORCES ANALYSIS

PART 08: PIPELINE ANALYSIS

PART 09: MARKET SEGMENTATION BY DRUG CLASS

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

PART 14: MARKET TRENDS

PART 15: VENDOR LANDSCAPE

PART 16: VENDOR ANALYSIS

PART 17: APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/m22w44/global_acromegaly?w=5

Media Contact:


Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 12:15
ResBiotic Nutrition, Inc. (ResBiotic), the pioneering physician-developed pre/probiotic wellness scale-up, proudly announces the appointments of Stefany Nieto as Vice President of Operations and Brittany Zenner as Director of Marketing. Nieto is a...

at 12:06
Maid Sailors Cleaning Service has joined forces with Cleaning for a Reason, a non-profit organization offering free house cleaning services to cancer patients across the United States and Canada....

at 12:05
Terragia Biofuel, a technology startup aiming to drive the next generation of biofuels, today announced it has raised a $6 million seed round led by Engine Ventures and Energy Impact Partners (EIP). The company will use the capital to commercialize...

at 12:05
Float, the marketplace moving all the care that doesn't need a hospital to the home, today announced $10 million in Series A funding led by Canvas Ventures, whose General Partner Mike Ghaffary has joined Float's board, with participation from Wave...

at 12:00
V-Wave today announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American College of Cardiology's (ACC) Annual Scientific Session & Expo taking place April 6-8 in Atlanta. RELIEVE-HF is a randomized, double-blind,...

at 12:00
Critical Path Institute's (C-Path) Duchenne Regulatory Science Consortium (D-RSC) is excited to announce the launch of a groundbreaking model-based Clinical Trial Simulator (CTS), specifically designed to improve design of efficacy studies for...



News published on and distributed by: